Drug Profile

GDD 3898

Alternative Names: GDD-3898

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lipidio Pharmaceuticals
Class Behavioural disorder therapies; Hepatoprotectants; Obesity therapies; Skin disorder therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2024 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease(In volunteers) in Australia (Topical, Gel)
10 Mar 2022 Lipidio Pharmaceuticals Australia plans a phase II trial for Hyperplasia in Australia (Topical) (ACTRN12622000008729)
08 Mar 2021 Lipidio Pharmaceuticals completes a phase I trial in Non-alcoholic fatty liver disease (In volunteers) in Australia (Topical) (ACTRN12621000255886)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com